Latest

Jul 17, 2026, 18:44 Arvind Krishna Rebuilt IBM Around Software. Now He Has to Make the AI Stack Outrun the Mainframe Cycle

Jul 17, 2026, 16:45 Nikhil Kamath Turned Market Access Into a Media Platform. Influence Now Needs Clearer Boundaries

Jul 17, 2026, 13:40 Lucy Guo Built Passes Around Creator Ownership. Trust Must Become the Subscription Advantage

Jul 17, 2026, 10:35 Shashank Kumar Is Rewiring Razorpay Around Payment Success. Reliability Has to Pay

Jul 16, 2026, 16:45 Ritesh Agarwal Has Taken PRISM Back to the IPO Gate. Investors Will Price the Quality of OYO's Profit

Jul 16, 2026, 15:37 Nikesh Arora Made Palo Alto Networks Cybersecurity’s Consolidator. Now He Has to Make the Stack Work as One

Jul 16, 2026, 13:40 Gukesh Dommaraju Became Chess's Youngest World Champion. Defending the Crown Is a Different Business

Jul 16, 2026, 10:35 Scott Wu Joined Devin With Windsurf. The Combined Product Must Earn a US$26 Billion Valuation

Daphne Koller

Daphne Koller, Founder and Chief Executive Officer of insitro

Daphne Koller’s $800 Million AI Bet Is Reaching Its First Human Trial Test

Daphne Koller has financed insitro with roughly $800 million in capital and collaboration revenue. Its first AI-discovered MASH programme is nearing the point where patients, not models, set the valuation.

Daphne Koller, founder and Chief Executive Officer of insitro

Daphne Koller Is Turning Insitro’s AI Platform Into Drug Candidates. Biology Still Sets the Clock

Daphne Koller has spent years building a machine-learning company around human biology. In 2026, insitro’s partnerships and preclinical programmes are beginning to test whether its data advantage can produce medicines rather than promising hypotheses.